<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Initial treatment of rheumatoid arthritis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Initial treatment of rheumatoid arthritis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Initial treatment of rheumatoid arthritis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stanley Cohen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ted R Mikuls, MD, MSPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R O'Dell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3692501"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The treatment of rheumatoid arthritis (RA) is directed toward the control of synovitis and the prevention of joint injury. Support for an early aggressive approach to treatment is based upon the observations that joint damage, which may ultimately result in disability, begins early in the course of disease and that the longer active disease persists, the less likely the patient is to respond to therapy [<a href="#rid1">1</a>]. Improved outcomes have resulted from the use of potent and well-tolerated nonbiologic (traditional), biologic, and targeted small molecule disease-modifying antirheumatic drugs (DMARDs) used alone or in combination to induce and maintain tight control of disease [<a href="#rid2">2-10</a>]. These medications and strategies have the potential to control synovitis and slow or stop radiographic progression [<a href="#rid2">2,9,11,12</a>].</p><p>These observations regarding the course of disease and the efficacy of these therapeutic approaches, coupled with limits in the ability to accurately identify individuals with a poor prognosis, support our view that every patient with established active RA should be treated with DMARDs at the earliest stage of disease, ideally within three months of symptom onset. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p>The treatment of patients with active RA with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) as initial DMARD monotherapy and regardless of duration will be reviewed here. The diagnosis and differential diagnosis, the general principles of management, and an overview of the therapy of RA, the initial treatment of RA using DMARD therapy other than MTX, and the treatment of disease resistant to initial therapy are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7504.html" rel="external">"Diagnosis and differential diagnosis of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a> and  <a class="medical medical_review" href="/z/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy"</a>.)</p><p class="headingAnchor" id="H3692872"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>There are several general principles important in the management of all patients with rheumatoid arthritis (RA). These principles are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p>Briefly, these include:</p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation and ongoing care by a rheumatologist</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Achievement and maintenance of tight control of disease activity, defined as remission or a state of low disease activity, without compromising safety</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of all patients diagnosed with RA with disease-modifying antirheumatic drug (DMARD) therapy following a shared decision-making process</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of antiinflammatory therapies, including nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids, to help control symptoms until DMARDs take effect</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification, management, and prevention of comorbid conditions that can complicate the disease course</p><p></p><p class="headingAnchor" id="H2985885"><span class="h1">NONPHARMACOLOGIC AND PREVENTIVE THERAPIES</span><span class="headingEndMark"> — </span>A number of nonpharmacologic measures and other medical interventions are important in the comprehensive management of rheumatoid arthritis (RA), in addition to antiinflammatory and antirheumatic drug therapies. These interventions, including patient education, exercise, rehabilitation, vaccinations, and others, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7498.html" rel="external">"Nonpharmacologic therapies for patients with rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H5"><span class="h1">APPROACH TO DRUG THERAPY</span><span class="headingEndMark"> — </span>Our approach to therapy is based upon the widely accepted view that all patients diagnosed with active rheumatoid arthritis (RA) should receive disease-modifying antirheumatic drugs (DMARDs) to prevent, arrest, or retard disease-related injury (see <a class="local">'General principles'</a> above). Recommendations of major groups support the early use of DMARDs, usually <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), for most patients with active disease [<a href="#rid13">13-17</a>].</p><p>The following is our general approach to the selection of drug therapies for the initial therapy of patients with active RA. It is broadly consistent with the 2021 American College of Rheumatology (ACR) recommendations and with the 2022 recommendations of the European Alliance of Associations for Rheumatology (EULAR; formerly known as European League Against Rheumatism) [<a href="#rid17">17,18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>We initiate therapy with a DMARD or combinations of DMARDs. We suggest MTX as the initial DMARD. (See <a class="local">'Initial therapy with methotrexate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients unable or unwilling to take MTX at the initiation of DMARD therapy, we use monotherapy with <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, or a tumor necrosis factor (TNF) inhibitor, depending upon comorbidities, patient preferences, regulatory guidance, and disease severity. (See  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We add nonsteroidal antiinflammatory drugs (NSAIDs) and/or glucocorticoids (systemic and/or intraarticular) for initial symptomatic control of inflammation while awaiting the response to DMARD therapy. We do not use NSAIDs or glucocorticoids as the sole or primary treatments. (See <a class="local">'NSAIDs'</a> below and <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients not achieving remission or low disease activity with appropriate doses of MTX monotherapy after three to six months, our preferred approach is to initiate combination therapy. (See <a class="local">'Inadequate treatment response'</a> below and <a class="local">'Monitoring and reevaluation'</a> below and  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a>.)</p><p></p><p class="headingAnchor" id="H3981569"><span class="h1">DMARD THERAPY</span><span class="headingEndMark"> — </span>We initially use one of the more effective disease-modifying antirheumatic drugs (DMARDs), usually <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), both to suppress synovitis and other signs and symptoms of active disease and to prevent articular bone erosions and joint space narrowing. We initiate DMARD therapy as early in the treatment of rheumatoid arthritis (RA) as possible because delayed use of such medications results in poorer physical function and increased joint injury [<a href="#rid19">19-21</a>]. Alternatives to MTX for initial DMARD therapy are described separately. (See  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a>.)</p><p>Numerous meta-analyses and randomized controlled trials support the use of nonbiologic (traditional) and biologic DMARDs in patients with active RA [<a href="#rid13">13,22-30</a>]. These trials included a mix of patients with a range of severity and a mean duration of illness of 6 to 12 months [<a href="#rid3">3,6,19,29-32</a>]. The applicability of these studies to the initial treatment of patients with active disease is addressed together with the other evidence described below.</p><p class="headingAnchor" id="H3981576"><span class="h2">Pretreatment interventions</span><span class="headingEndMark"> — </span>We take a number of important precautions before using DMARDs, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory assessment (eg, complete blood count, serum creatinine, aminotransferases)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for hepatitis C, hepatitis B, and latent tuberculosis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring that the patient has received standard immunizations</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest radiograph for patients initiating MTX therapy</p><p></p><p>Although not conclusive, observational data have suggested that there may be an increased risk of MTX hypersensitivity pneumonitis in patients with underlying pulmonary disease, and having a baseline chest radiograph in these patients would be helpful for subsequent comparison if needed. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Pulmonary toxicity'</a> and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H3981583"><span class="h2">Initial therapy with methotrexate</span><span class="headingEndMark"> — </span>We suggest MTX as the DMARD of choice for the initial treatment of patients with active RA. MTX typically serves as the "anchor" drug for the most commonly used DMARD combinations [<a href="#rid33">33-35</a>]. The major issues regarding the use of MTX in RA will be briefly reviewed here but are discussed in further detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases"</a>.)</p><p>MTX is <strong>contraindicated</strong> in several groups of patients. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Women who are contemplating becoming pregnant or women not using adequate contraception</p><p class="bulletIndent1"><span class="glyph">●</span>Women who are pregnant</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with liver disease or excessive alcohol intake</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL/min)</p><p></p><p>Issues related to the use of MTX and reproductive health are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Methotrexate'</a> and  <a class="medical medical_review" href="/z/d/html/15904.html" rel="external">"Effects of antiinflammatory and immunosuppressive drugs on gonadal function and teratogenicity in men with rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H3982770"><span class="h3">Methotrexate dosing</span><span class="headingEndMark"> — </span>MTX is given in a <strong>single weekly</strong> dose, usually orally. The optimal starting dose and schedule for dose escalation are uncertain. We suggest initiating therapy at a dose between 7.5 and 15 mg once weekly for most patients, depending upon the degree of disease activity, the size and age of the patient, the presence of comorbidities, and renal function. As examples, we would treat a 70-year-old patient weighing 55 kg with moderately active disease with an initial dose of 7.5 mg once weekly, while an otherwise healthy 30-year-old patient weighing 80 kg with highly active disease would be started on 15 mg once weekly. A lower initial dose is essential in patients with reduced renal function, defined as an eGFR &lt;60 mL/min. Initial subcutaneous dosing is an alternative favored by some experts [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a> and  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dose titration'</a>.)</p><p>The MTX dose is increased as tolerated and as needed to control symptoms and signs of arthritis. Our usual approach is to increase the dose after four weeks by 2.5 mg (one tablet) to 5 mg per week at intervals no more frequent than every month, as indicated by disease activity and as tolerated (eg, from 10 mg initially to 15 mg once weekly after four weeks of initial therapy, then after a month on the higher dose it can be increased as tolerated to 17.5 or 20 mg once weekly if the response has been inadequate). In patients with continued high disease activity, we may increase by up to 5 mg/week if few comorbidities are present and if the increase in the dose continues to be well-tolerated. The usual target dose is at least 15 mg/week; the usual maximum dose is 25 mg/week. Alternative dose titration strategies may also be employed. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dose titration'</a>.)</p><p>In early RA trials in which the dose of MTX is rapidly increased to 20 mg/week and in which the drug is continued for at least three months, approximately 30 percent of patients achieve a Disease Activity Score 28 (DAS28) less than or equal to 3.2, consistent with low disease activity, within three to six months [<a href="#rid37">37,38</a>].</p><p>For patients in whom 15 to 25 mg of MTX orally once weekly is ineffective or is poorly tolerated because of gastrointestinal symptoms, a trial of subcutaneous MTX administration is an alternative to switching to another DMARD or to adding other conventional DMARDs or a tumor necrosis factor (TNF) inhibitor. As an alternative to subcutaneous dosing, a dose of 15 mg or greater of MTX can be administered orally in a split dose with both doses taken on the same day of the week to enhance absorption, as MTX is better absorbed when administered in lower individual doses [<a href="#rid39">39</a>]. It is imperative to tell the patient to take all the MTX over a single 24-hour period once a week, as spreading the dose out further may produce significant liver toxicity. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a> and  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Parenteral therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Pharmacology'</a> and  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Split dosing'</a>.)</p><p class="headingAnchor" id="H3984111"><span class="h3">Side effects, monitoring, and other considerations</span><span class="headingEndMark"> — </span>MTX treatment requires meticulous monitoring for bone marrow, liver, and lung toxicity. The toxicities associated with MTX in the doses used in RA are very rarely life-threatening in patients receiving recommended monitoring. MTX is generally well-tolerated, although most patients experience at least one or more of the more common side effects, such as gastrointestinal upset or stomatitis, over their course of therapy. Although concomitant use of certain medicines (such as nonsteroidal antiinflammatory drugs [NSAIDs] or proton pump inhibitors) can increase MTX drug levels, this typically has little clinical consequence given the relatively low weekly doses used in RA compared with the substantially higher doses used in the treatment of some cancers. MTX is discontinued due to adverse effects after two and five years of treatment in up to 20 and 35 percent of patients, respectively [<a href="#rid24">24</a>]. The major side effects of low-dose MTX are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a> and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p>Patients receiving MTX should also receive daily supplementation with <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a>. The use of folic acid and additional considerations with the use of MTX that are discussed in more detail separately include alcohol ingestion and dosing in renal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H207103444"><span class="h3">Methotrexate versus other DMARDs</span><span class="headingEndMark"> — </span>Randomized head-to-head trials have found that MTX has a faster onset of action, comparable or greater efficacy, and better long-term tolerance compared with other nonbiologic DMARD monotherapy [<a href="#rid24">24</a>]. MTX has also been shown to improve survival (both cardiovascular and all-cause mortality) in patients with RA compared with other nonbiologic DMARDs [<a href="#rid40">40,41</a>]. <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, and <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> have been used as alternatives to MTX due to intolerance or when MTX is contraindicated.</p><p>Two trials that supported the initial regulatory approval of <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> for RA that were conducted in the 1990s compared leflunomide (20 mg daily after a loading dose of 100 mg daily for three days) with MTX at 10 to 15 mg once weekly, a dose lower than that subsequently both widely used and considered as optimal [<a href="#rid42">42,43</a>]. One trial demonstrated similar efficacy of leflunomide to MTX with both being superior to placebo, and the second, larger head-to-head study demonstrated that MTX was superior to leflunomide in the individual components of the American College of Rheumatology (ACR) clinical response. Due to the greater cost of leflunomide and the side effect profile, MTX has remained the preferred initial DMARD. <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> had similar efficacy to leflunomide in a single randomized trial, but persistence on therapy was poor [<a href="#rid44">44</a>].</p><p>MTX has been shown to be beneficial both in patients with longstanding and earlier disease. As an example, in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) study, which compared initiation of combination therapies with initiating MTX monotherapy and stepping up therapy in patients who did not achieve low disease activity at six months, patients were enrolled with disease duration of only three to four months. Twenty-eight percent of patients treated with MTX monotherapy achieved low disease activity (LDA), defined as DAS28-erythrocyte sedimentation rate (ESR) &lt;3.2 [<a href="#rid45">45</a>]. Similar clinical efficacy has been noted in multiple randomized trials that compared MTX monotherapy with MTX combination therapies.</p><p>The benefits and safety of MTX have also been documented in multiple other randomized trials and long-term observational studies, including in comparison with placebo and with other DMARD therapies [<a href="#rid46">46-55</a>].</p><p>In randomized trials, initial therapy with MTX results in comparable clinical benefit compared with initial therapy with TNF inhibitor monotherapy, but radiographic benefit may be numerically less [<a href="#rid29">29,30</a>]. Trials have also demonstrated superior efficacy to MTX in early RA of the Janus kinase inhibitors <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a>, but these therapies have rarely been used in early RA due to their substantially greater cost and side effect profile demonstrated in comparisons with TNF inhibitors [<a href="#rid56">56-59</a>]. A recent open-label phase IV trial (NORDSTAR) compared <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> rapidly escalated to 25 mg along with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper or as triple therapy with <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, or certolizumab in combination with methotrexate in early seropositive RA patients. Adjusted 24-week Clinical Disease Activity Index (CDAI) remission rates were 42.7 percent (95% CI 36.1-49.3 percent) for active conventional treatment, 46.5 percent (95% CI 39.9-53.1 percent) for <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>, 52.0 percent (45.5-58.6 percent) for abatacept, and 42.1 percent (35.3-48.8 percent) for tocilizumab with abatacept demonstrating superiority compared with conventional therapy. Adjusted CDAI remission rates at week 48 were 59.3 percent (abatacept), 52.3 percent (certolizumab), 51.9 percent (tocilizumab), and 39.2 percent (active conventional therapy), with both abatacept and certolizumab statistically superior. Radiographic progression was low with no group differences [<a href="#rid60">60</a>]. Tight control treatment strategies have also shown significant benefit without the use of biologics for initial therapy [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Tight control'</a>.)</p><p class="headingAnchor" id="H207103451"><span class="h3">Methotrexate versus initial combination therapy</span><span class="headingEndMark"> — </span>Combinations of MTX with either <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a> or <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, with both sulfasalazine and hydroxychloroquine (commonly referred to as "triple therapy" or "triple DMARD therapy"), or with a biologic DMARD also have proven efficacy for initial treatment of highly active RA [<a href="#rid13">13,62</a>]. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'General approach'</a>.)</p><p>However, we prefer MTX monotherapy for initial treatment rather than in combination with other nonbiologic or biologic DMARDs or a biologic DMARD alone, despite the fact that a greater proportion of patients respond well when treated initially with combination therapies or biologics, and observations that MTX and biologics have a similar frequency of long-term side effects [<a href="#rid62">62</a>]. This is principally because:</p><p class="bulletIndent1"><span class="glyph">●</span>Initial MTX monotherapy is adequate in many patients with early, moderately to severely active RA; those with an inadequate response can be quickly identified and subsequently treated with combination therapy prior to the development of irreversible injury [<a href="#rid29">29,30,37,61,63,64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical outcomes after several years of treatment are similar in trials that compared patients initially receiving MTX, who then stepped up to combination therapy after an inadequate response, with patients initially treated with combination therapy. This was best demonstrated in a post-hoc analysis of the TEAR trial, a blinded randomized trial of this approach [<a href="#rid65">65</a>]. In this analysis, the clinical outcomes from weeks 48 to 102 in patients who had been stepped up from MTX alone, based upon clinical findings after six months (DAS28-ESR ≥3.2), to receive combination therapy (either triple therapy with traditional DMARDs or MTX plus <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>) were comparable to patients started on combination therapy initially. Longer-term clinical outcomes between such groups are otherwise not well-studied.</p><p></p><p class="bulletIndent1">In the TEAR trial, there was also no difference at two years in radiographic outcomes between the patients initially assigned to MTX only and those assigned to combination therapy [<a href="#rid65">65</a>]. When differences between these approaches have been described, they have tended to favor the combination groups, but have been very small and of uncertain clinical significance [<a href="#rid4">4,37,66,67</a>]. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy", section on 'Efficacy of triple DMARD therapy versus methotrexate/TNF inhibitor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are widespread regulatory or cost barriers to the use of biologic therapies for initial DMARD treatment for most DMARD-naïve patients, even with severely active RA.</p><p></p><p class="headingAnchor" id="H919605925"><span class="h2">Alternatives to methotrexate</span><span class="headingEndMark"> — </span>In patients unable or unwilling to take MTX, we use <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">sulfasalazine</a>, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, or a TNF inhibitor (eg, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> or <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>). <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">Tofacitinib</a>, <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a>, and <a class="drug drug_general" data-topicid="122341" href="/z/d/drug information/122341.html" rel="external">upadacitinib</a> are also effective in such patients. There are insufficient data to identify the optimal initial therapy in patients who are unable to take MTX. The choice of agent is largely based upon indirect comparisons; limited head-to-head comparisons; regulatory or insurance requirements; comorbidities; disease severity; and patient preferences regarding relative risks and benefits, route of administration, and cost. (See  <a class="medical medical_review" href="/z/d/html/7477.html" rel="external">"Alternatives to methotrexate for the initial treatment of rheumatoid arthritis in adults"</a>.)</p><p class="headingAnchor" id="H3694939"><span class="h1">SYMPTOMATIC TREATMENT WITH ANTIINFLAMMATORY DRUGS</span><span class="headingEndMark"> — </span>Nonsteroidal antiinflammatory drugs (NSAIDs) and/or glucocorticoids act rapidly to control inflammation but do not provide adequate benefit for longer-term control of disease or prevention of joint injury in most patients. Moreover, chronic use of these agents, particularly glucocorticoids in moderate to high doses, is associated with significant risk of adverse effects, with some data suggesting that the risk of serious infection associated with chronic glucocorticoid use is increased even at daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> doses ≤5 mg [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs", section on 'Toxicities and possible toxicities'</a>.)</p><p>We thus use these medications primarily for temporary control of disease activity in patients in whom treatment is being started with disease-modifying antirheumatic drugs (DMARDs) or in whom adjunctive treatment is needed for persistent or flaring disease until treatment with DMARDs is sufficiently effective. Some patients require ongoing use of such agents despite other therapies, but neither NSAIDs nor glucocorticoids should be considered as substitutes for effective treatment with DMARDs. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p>We use NSAIDs initially in most patients with active disease. We also initiate therapy with glucocorticoids in patients on the more severe end of this spectrum, while patients with less active disease who do not respond adequately to NSAIDs within two weeks should also receive treatment with glucocorticoids.</p><p class="headingAnchor" id="H3693478"><span class="h2">NSAIDs</span><span class="headingEndMark"> — </span>NSAIDs should be used at full therapeutic antiinflammatory doses for initial therapy of patients with active rheumatoid arthritis (RA), unless contraindicated by gastrointestinal, renal, or cardiovascular disease. NSAIDs also provide analgesic benefit.</p><p>NSAIDs are continued for at least two weeks before switching agents, because maximal analgesic and antiinflammatory effect is usually achieved within 10 to 14 days. The dose and duration of NSAIDs previously tried by the patient should be identified to determine if an adequate trial of one or more NSAIDs has already been attempted. The dose of a given medication required by different patients may vary. Examples of effective total daily doses include 2400 to 3200 mg of <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, 1000 mg of <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, or a single daily dose of a longer-acting agent such as 15 mg of <a class="drug drug_general" data-topicid="10295" href="/z/d/drug information/10295.html" rel="external">meloxicam</a>.</p><p>A reduced dose and more frequent monitoring may be needed in older patients and in others who may be at greater risk of adverse effects, including renal insufficiency due to comorbidities or other medication use and those with increased cardiovascular risk. The use and safety of NSAIDs in patients with renal disease and in those with cardiovascular disease and increased cardiovascular risk are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a> and  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects", section on 'Renal effects'</a>.)</p><p>With usual drug safety monitoring, NSAIDs can be used with concomitant DMARDs, including <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), without dose adjustment. (See  <a class="medical medical_review" href="/z/d/html/7993.html" rel="external">"NSAIDs: Therapeutic use and variability of response in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs"</a>.)</p><p>In patients at increased risk of NSAID gastropathy, such as those who are also receiving glucocorticoids or who have a history of peptic ulcer disease, appropriate measures should be undertaken to decrease the risk of gastrointestinal complications such as use of a proton pump inhibitor, <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">misoprostol</a>, or possibly use of a selective cyclooxygenase (COX)-2 inhibitor (eg, <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>) rather than a nonselective NSAID. Alternatives to the non-salicylate NSAIDs in such patients also include the non-acetylated salicylates (eg, <a class="drug drug_general" data-topicid="9876" href="/z/d/drug information/9876.html" rel="external">salsalate</a> at 2000 to 3000 mg/day), which have proven antiinflammatory activity with fewer adverse gastrointestinal effects. (See  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a> and  <a class="medical medical_review" href="/z/d/html/14.html" rel="external">"NSAIDs (including aspirin): Treatment and secondary prevention of gastroduodenal toxicity"</a>.)</p><p>Patients should be cautioned regarding the risks of chronic use of NSAIDs. Effective management with DMARDs should allow for the discontinuation of daily full-dose NSAID use. (See  <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p>Therapeutic trials of individual NSAIDs can continue until the patient has achieved adequate control of the inflammation with minimal side effects. Clinical experience indicates that there are relatively little or no benefits and an increased risk of gastrointestinal toxicity when adding one NSAID to another. Treatment with glucocorticoids should be offered if adequate symptomatic relief is not achieved within 10 to 14 days on NSAIDs alone while awaiting benefit from DMARD therapy. (See  <a class="medical medical_review" href="/z/d/html/8.html" rel="external">"NSAIDs (including aspirin): Pathogenesis and risk factors for gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H3693989"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids act to rapidly reduce symptoms due to inflammatory synovitis in patients with RA. Oral glucocorticoids are commonly used in RA, and some patients may benefit from intraarticular or intramuscular glucocorticoid administration in this setting. Glucocorticoid use is discussed briefly below. A more detailed discussion of glucocorticoid use in RA and of the data supporting its efficacy is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis"</a> and <a class="local">'Therapy for resistant disease and flares'</a> below and <a class="local">'Intraarticular glucocorticoids'</a> below and <a class="local">'Intramuscular glucocorticoids'</a> below and <a class="local">'Oral glucocorticoids'</a> below.)</p><p>There is also evidence that glucocorticoids retard radiographic progression in patients with RA in the short to medium term [<a href="#rid69">69-71</a>]. However, these agents should not be used alone for an extended period, and long-term treatment with glucocorticoids should be minimized since their use may be associated with increased morbidity and mortality [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis", section on 'Efficacy of chronic use'</a>.)</p><p class="headingAnchor" id="H3695299"><span class="h3">Oral glucocorticoids</span><span class="headingEndMark"> — </span>We suggest the use of oral glucocorticoids to help control disease activity in the initial treatment of severely active RA, particularly in early disease, and in the treatment of patients with less severe disease in whom a trial of NSAIDs has been inadequate. We use glucocorticoids in addition to (or sometimes in place of) NSAIDs because of their extremely rapid onset of action and the greater effectiveness in controlling symptoms for most patients with active RA [<a href="#rid73">73</a>]. Based upon our clinical experience, we usually initiate therapy with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 to 20 mg/day, depending upon the severity of joint inflammation and upon the minimal dose required to obtain initial control. Most patients can be adequately controlled on 5 to 10 mg/day while initiating DMARDs.</p><p>Glucocorticoids should then be tapered as rapidly as tolerated with the goal of further tapering and eventual discontinuation, if possible, once disease control is achieved and can be maintained. In general, the beneficial effects of DMARD therapy will permit reduction and discontinuation of the glucocorticoids, a goal of successful DMARD therapy, within four to six months. (See  <a class="medical medical_review" href="/z/d/html/7983.html" rel="external">"Glucocorticoid withdrawal"</a>.)</p><p>The efficacy of glucocorticoids in this setting has been shown in randomized trials and in a large number of observational studies [<a href="#rid73">73</a>]. Some studies have used relatively high-dose glucocorticoids for initial therapy (<a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 60 mg/day or equivalent) [<a href="#rid3">3,74</a>]. However, lower doses are usually adequate when combined with effective DMARDs. (See  <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis"</a>.)</p><p>There are numerous risks associated with glucocorticoid use, and appropriate monitoring and precautions should be performed in all patients on these medications with respect to risks for osteoporosis, diabetes, infection [<a href="#rid75">75</a>], and other adverse effects of hypercortisolism. RA is considered an independent risk factor for osteoporotic fracture, and a fracture risk assessment should be performed to help guide treatment decisions. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a> and  <a class="medical medical_review" href="/z/d/html/2061.html" rel="external">"Osteoporotic fracture risk assessment", section on 'Assessment of fracture risk'</a> and  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H1487863"><span class="h3">Intramuscular glucocorticoids</span><span class="headingEndMark"> — </span>In patients who must avoid daily oral glucocorticoids or who require an extremely rapid antiinflammatory response, an alternative to oral glucocorticoids is a single initial intramuscular injection of a depot preparation of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> (80 to 120 mg), administered by deep intramuscular injection into the gluteal muscle [<a href="#rid76">76-78</a>]. Based upon the overall clinical response, up to two subsequent injections may be required at intervals of every four weeks to maintain improvement in symptoms, signs, and physical function, while slower-acting DMARDs exert their expected effect on controlling disease activity. Longer-term use is avoided to prevent harmful effects of glucocorticoids [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H3985847"><span class="h3">Intraarticular glucocorticoids</span><span class="headingEndMark"> — </span>Intraarticular injections of long-acting glucocorticoids (eg, <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> hexacetonide) are used to reduce synovitis in particular joints that are more inflamed than others. In such patients, it may be difficult to distinguish between active joint inflammation due to RA alone and that due to infection. Thus, when clinically indicated, joint fluid should be obtained to exclude infection. (See  <a class="medical medical_review" href="/z/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis"</a> and  <a class="medical medical_review" href="/z/d/html/7985.html" rel="external">"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?"</a>.)</p><p class="headingAnchor" id="H2986439"><span class="h1">ANALGESICS</span><span class="headingEndMark"> — </span>In addition to the medications noted above, we use analgesic medications, such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, for additional pain relief if required. We avoid the use of opioids because pain can be controlled in most patients with rheumatoid arthritis (RA) by effective use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, and disease-modifying antirheumatic drugs (DMARDs) that control the disease process. Patients without evidence of very significant joint injury who appear to require opioids for adequate pain relief despite good control of disease activity should be evaluated for other comorbid conditions.</p><p class="headingAnchor" id="H21"><span class="h1">MONITORING AND REEVALUATION</span><span class="headingEndMark"> — </span>Disease activity and the response to therapy should be regularly reassessed, along with monitoring for drug toxicities, every three to five weeks until the patient is stable and disease is under control [<a href="#rid9">9,69,79,80</a>]. Subsequently, frequency of assessments should generally be no fewer than every three months. Well-controlled patients who are seen less frequently may require laboratory monitoring beyond that performed at scheduled visits and should be counseled, as should all patients, to contact their treating clinician if the arthritis flares. Laboratory testing for the monitoring of disease activity and for the monitoring and prevention of drug toxicity is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Drug monitoring and prevention of drug toxicity'</a>.)</p><p>We periodically reevaluate and track disease activity using a quantitative composite measure at each assessment. Recommended measures are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7494.html" rel="external">"Assessment of rheumatoid arthritis disease activity and physical function"</a> and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Tight control'</a>.)</p><p>Adaptations of measures for the assessment of disease activity and function have been proposed for the monitoring of patients receiving care during telehealth visits [<a href="#rid81">81</a>].</p><p>More frequent laboratory monitoring may be required depending on the medications being used and following increases in dosing; more frequent clinical assessments may be required in patients with comorbidity or in those experiencing a flare of disease or undergoing changes in therapy. We alter therapy if the disease remains active or progresses. (See <a class="local">'Disease resistant to initial methotrexate therapy'</a> below.)</p><p class="headingAnchor" id="H1488242"><span class="h1">THERAPY FOR RESISTANT DISEASE AND FLARES</span></p><p class="headingAnchor" id="H3985983"><span class="h2">Disease resistant to initial symptomatic treatment</span><span class="headingEndMark"> — </span>We take the following approaches in patients who exhibit a persistent inflammatory synovitis that is resistant to the initial symptomatic therapies described above:</p><p class="bulletIndent1"><span class="glyph">●</span>We add oral glucocorticoids in patients begun on nonsteroidal antiinflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs) who continue to experience significant symptoms after 10 to 14 days of therapy. (See <a class="local">'Oral glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We use intraarticular glucocorticoids in individual joints when only a small number are resistant to therapy with systemic agents, or if it is anticipated that a local injection may preclude the need for NSAIDs or systemic glucocorticoids. (See <a class="local">'Intraarticular glucocorticoids'</a> above.)</p><p></p><p class="headingAnchor" id="H3986086"><span class="h2">Flares</span><span class="headingEndMark"> — </span>Rheumatoid arthritis (RA) has natural exacerbations (also known as flares) and reductions of continuing disease activity. It is important to distinguish a disease flare, characterized by symptoms and physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain. The severity of the flare and background drug therapy influence the choice of therapies. Drug therapy for flares is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Drug therapy for flares'</a>.)</p><p class="headingAnchor" id="H3718756872"><span class="h2">Disease resistant to initial methotrexate therapy</span><span class="headingEndMark"> — </span>In patients resistant to initial DMARD therapy with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX), we either add additional DMARDs or switch the patient to a different DMARD or DMARD combination, while also treating the active inflammation with antiinflammatory drug therapy. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a>.)</p><p class="headingAnchor" id="H3697757"><span class="h1">DURATION OF THERAPY</span></p><p class="headingAnchor" id="H992836183"><span class="h2">Inadequate treatment response</span><span class="headingEndMark"> — </span>We suggest that patients who fail to achieve remission or low disease activity within three to six months of initiating therapy, or who require more than approximately 5 to 7.5 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent glucocorticoid chronically to maintain a state of remission or low disease activity, undergo a change in therapeutic regimen. The decision to intensify or modify treatment also depends, in part, upon the patient's functional capacity and quality of life. We would typically make a change in therapy in patients who continue to have moderate to high disease activity despite optimized <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) dosing after three months, even if they have had some benefit. Patients with a substantial reduction in disease activity both proportionally (eg, over 50 percent) and in absolute terms (eg, reduction in a Disease Activity Score 28 [DAS28] of &gt;1.2) might have such changes deferred to six months, even if minimal disease activity has not yet been achieved, depending upon their goals and preferences. (See  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a>.)</p><p class="headingAnchor" id="H2315752641"><span class="h2">Adequate treatment response</span><span class="headingEndMark"> — </span>Most patients with active rheumatoid arthritis (RA) will require sustained therapy and adjustments in their treatment regimen over months to years to achieve treatment goals. In the minority of patients who achieve a sustained clinical remission of greater than one year, we cautiously try to reduce disease-modifying antirheumatic drug (DMARD) doses while maintaining close monitoring to facilitate recognition of any recurrence of disease activity. Although some patients may tolerate a reduced dose of medications, whether or not to discontinue DMARDs in patients in remission remains controversial [<a href="#rid14">14,82,83</a>]. We prefer to continue nonbiologic or biologic DMARD therapy at reduced doses, if possible, but do not discontinue DMARD therapy in most patients who have had active RA. Cautious reduction of biologic DMARD doses can be performed by increasing the interval between doses or by reducing the medication dose [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Assessment and monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Tight control'</a>.)</p><p>As an example, in a patient in clinical remission being treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (7.5 mg/day) and MTX (20 mg/week), we would first try to reduce prednisone because of the risk of long-term adverse effects with glucocorticoids. In such a patient, we would lower the glucocorticoid dose slowly (no faster than an average of 1 mg every two to four weeks), as long as there was no recurrence of disease activity. If prednisone can be discontinued, or cannot but can be lowered to a dose no greater than 5 mg/day, we next decrease MTX. We reduce the MTX dose in 2.5 mg increments every two to three months as tolerated but generally to no lower than 15 mg/week. A lower dose of MTX (eg, 10 to 12.5 mg/week) may be adequate to maintain remission in patients who are older or who have diminished renal function.</p><p>Continued close monitoring is required in patients who discontinue their medications and who enter a period of possible drug-free remission. The risk of disease recurrence in such patients is high, and flares of disease may occur even several years after stopping therapy [<a href="#rid82">82,84-88</a>]. Additionally, clinical remission may be difficult to achieve upon resumption of DMARD therapy in patients who have discontinued all DMARDs. The best candidates for achieving a drug-free remission appear to be patients with the following characteristics: a short duration of symptoms when treatment is started, male sex, the absence of autoantibodies, and receipt of early intensive therapy [<a href="#rid74">74,86,88,89</a>].</p><p class="headingAnchor" id="H366807650"><span class="h1">PREGNANCY, COMORBIDITIES, AND OTHER SPECIAL CONSIDERATIONS</span><span class="headingEndMark"> — </span>Pregnancy and the presence of comorbidities, such as renal or hepatic disease, may affect medication choices and may influence the degree of risk inherent in attempting to reach a goal of remission or of low disease activity in a given patient. A number of medical conditions that often coexist with or result from rheumatoid arthritis (RA) may influence the choice of medications. The approach to treatment in the presence of these conditions is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults", section on 'Tight control'</a> and  <a class="medical medical_review" href="/z/d/html/7514.html" rel="external">"Rheumatoid arthritis and pregnancy"</a>.)</p><p class="headingAnchor" id="H272291268"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116127.html" rel="external">"Society guideline links: Rheumatoid arthritis"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15445.html" rel="external">"Patient education: Rheumatoid arthritis (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86834.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/512.html" rel="external">"Patient education: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/513.html" rel="external">"Patient education: Rheumatoid arthritis treatment (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/583.html" rel="external">"Patient education: Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to management</strong> – In all patients with active rheumatoid arthritis (RA), we recommend treatment with a disease-modifying antirheumatic drug (DMARD), rather than use of antiinflammatory agents and/or glucocorticoids alone and delaying DMARD therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Additional principles for the treatment of RA include achievement and maintenance of tight control of disease activity, with the ideal goal of remission; use of antiinflammatory agents, including nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids, only as adjunctive agents; and participation of a rheumatologist in the evaluation and ongoing care of the patient. (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">"General principles and overview of management of rheumatoid arthritis in adults"</a>.)</p><p></p><p class="bulletIndent1">Patient education and other nonpharmacologic and preventive therapies are needed for all patients with RA. (See <a class="local">'Nonpharmacologic and preventive therapies'</a> above and  <a class="medical medical_review" href="/z/d/html/7498.html" rel="external">"Nonpharmacologic therapies for patients with rheumatoid arthritis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial immunosuppressive therapy</strong> – In patients with active RA we suggest <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) as the initial DMARD, rather than another single nonbiologic or biologic DMARD or combination therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Doses are increased as tolerated and as needed, up to 25 mg/week, to control symptoms and signs of arthritis. Subcutaneous administration may be of benefit in patients with an inadequate response to orally administered MTX at a dose of 15 to 25 mg/week of MTX. (See <a class="local">'Initial therapy with methotrexate'</a> above.)</p><p></p><p class="bulletIndent1">In patients who are unable or unwilling to take MTX, we use an alternative nonbiologic or biologic DMARD therapy. (See <a class="local">'Alternatives to methotrexate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom management</strong> – In patients with active RA, we use antiinflammatory drug therapy with NSAIDs or glucocorticoids, preferably on a temporary basis, to quickly achieve control of signs and symptoms of disease. We use NSAIDs in all patients without contraindications to their use. In patients with more severe disease or with moderate disease resistant to a brief course of NSAIDs, we suggest the use of glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We then taper and withdraw these medications once DMARDs have taken effect. We use intraarticular injections of long-acting glucocorticoids to reduce synovitis in particular joints that are more inflamed than others. When clinically indicated, joint fluid should be obtained to exclude infection. (See <a class="local">'NSAIDs'</a> above and <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – During the initial treatment of patients with active RA, the patient should be reevaluated every three to five weeks for the effectiveness of therapy and for the monitoring of possible drug toxicity. We advise regular reevaluation of disease activity using a quantitative composite measure at each assessment. In patients who fail to achieve remission within three to six months of initiating optimal therapy, or who require more than approximately 5 to 7.5 mg/day of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent glucocorticoid on a chronic basis to maintain a state of remission or low disease activity, we use a more potent DMARD or combination of DMARDs rather than continuing the same treatment regimen for a longer period of time. The approach to these patients is described in detail separately. (See <a class="local">'Monitoring and reevaluation'</a> above and <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/z/d/html/7490.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial conventional synthetic (nonbiologic) DMARD therapy"</a>.)</p><p></p><p class="headingAnchor" id="H2277130239"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Peter H Schur, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22.</a></li><li><a class="nounderline abstract_t">Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69:638.</a></li><li><a class="nounderline abstract_t">Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.</a></li><li><a class="nounderline abstract_t">Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406.</a></li><li><a class="nounderline abstract_t">de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293.</a></li><li><a class="nounderline abstract_t">Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.</a></li><li><a class="nounderline abstract_t">Puolakka K, Kautiainen H, Möttönen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55.</a></li><li><a class="nounderline abstract_t">Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222.</a></li><li><a class="nounderline abstract_t">Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.</a></li><li><a class="nounderline abstract_t">Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443.</a></li><li><a class="nounderline abstract_t">Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.</a></li><li><a class="nounderline abstract_t">Sokka T, Kautiainen H, Häkkinen A, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004; 31:1073.</a></li><li><a class="nounderline abstract_t">Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.</a></li><li><a class="nounderline abstract_t">Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68:1.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492.</a></li><li><a class="nounderline abstract_t">Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2021; 73:1108.</a></li><li><a class="nounderline abstract_t">Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2023; 82:3.</a></li><li><a class="nounderline abstract_t">Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 2006; 55:864.</a></li><li><a class="nounderline abstract_t">Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111:446.</a></li><li><a class="nounderline abstract_t">Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906.</a></li><li class="breakAll">National Institute for Health and Clinical Excellence. Rheumatoid arthritis: The management of rheumatoid arthritis in adults http://guidance.nice.org.uk/CG79 (Accessed on March 29, 2010).</li><li><a class="nounderline abstract_t">Suarez-Almazor ME, Belseck E, Shea B, et al. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; :CD000957.</a></li><li><a class="nounderline abstract_t">Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39:975.</a></li><li><a class="nounderline abstract_t">Maddison P, Kiely P, Kirkham B, et al. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) 2005; 44:280.</a></li><li><a class="nounderline abstract_t">Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.</a></li><li><a class="nounderline abstract_t">Choy EH, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005; 44:1414.</a></li><li><a class="nounderline abstract_t">Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181:787.</a></li><li><a class="nounderline abstract_t">Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586.</a></li><li><a class="nounderline abstract_t">Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26.</a></li><li><a class="nounderline abstract_t">Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309.</a></li><li><a class="nounderline abstract_t">Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008; 58:1310.</a></li><li><a class="nounderline abstract_t">American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.</a></li><li><a class="nounderline abstract_t">Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998; 25:2331.</a></li><li><a class="nounderline abstract_t">van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5:531.</a></li><li><a class="nounderline abstract_t">Moura CS, Schieir O, Valois MF, et al. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. Arthritis Care Res (Hoboken) 2020; 72:1104.</a></li><li><a class="nounderline abstract_t">Moreland LW, O'Dell JR, Paulus H, et al. TEAR: Treatment of early aggressive RA: A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum 2009; 60:S707.</a></li><li><a class="nounderline abstract_t">Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008; 372:375.</a></li><li><a class="nounderline abstract_t">Hoekstra M, Haagsma C, Neef C, et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 2006; 33:481.</a></li><li><a class="nounderline abstract_t">Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173.</a></li><li><a class="nounderline abstract_t">Wasko MC, Dasgupta A, Hubert H, et al. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65:334.</a></li><li><a class="nounderline abstract_t">Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542.</a></li><li><a class="nounderline abstract_t">Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:655.</a></li><li><a class="nounderline abstract_t">Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353:259.</a></li><li><a class="nounderline abstract_t">Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012; 64:2824.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:818.</a></li><li><a class="nounderline abstract_t">Andersen PA, West SG, O'Dell JR, et al. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 1985; 103:489.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992; 35:129.</a></li><li><a class="nounderline abstract_t">Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994; 37:1492.</a></li><li><a class="nounderline abstract_t">Williams HJ, Willkens RF, Samuelson CO Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 1985; 28:721.</a></li><li><a class="nounderline abstract_t">Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. Arthritis Rheum 1997; 40:984.</a></li><li><a class="nounderline abstract_t">Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 2014; :CD000957.</a></li><li><a class="nounderline abstract_t">Maravic M, Bologna C, Daures JP, et al. Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol 1999; 26:262.</a></li><li><a class="nounderline abstract_t">Rich E, Moreland LW, Alarcón GS. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug. J Rheumatol 1999; 26:259.</a></li><li><a class="nounderline abstract_t">Rau R, Schleusser B, Herborn G, Karger T. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997; 24:1881.</a></li><li><a class="nounderline abstract_t">Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370:2377.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. Arthritis Rheumatol 2017; 69:506.</a></li><li><a class="nounderline abstract_t">van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. Arthritis Rheumatol 2020; 72:1607.</a></li><li><a class="nounderline abstract_t">Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022; 386:316.</a></li><li><a class="nounderline abstract_t">Hetland ML, Haavardsholm EA, Rudin A, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 2020; 371:m4328.</a></li><li><a class="nounderline abstract_t">Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374:430.</a></li><li><a class="nounderline abstract_t">Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2010; 49:91.</a></li><li><a class="nounderline abstract_t">Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010; 62:674.</a></li><li><a class="nounderline abstract_t">St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.</a></li><li><a class="nounderline abstract_t">O'Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum 2013; 65:1985.</a></li><li><a class="nounderline abstract_t">Moreland LW, O'Dell JR, Paulus HE, et al. Two-year radiographic results from the TEAR trial. Arthritis Rheum 2010; 62:S568.</a></li><li><a class="nounderline abstract_t">McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69:1898.</a></li><li><a class="nounderline abstract_t">George MD, Baker JF, Winthrop K, et al. Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. Ann Intern Med 2020; 173:870.</a></li><li><a class="nounderline abstract_t">Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Med Clin North Am 1997; 81:57.</a></li><li><a class="nounderline abstract_t">Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333:142.</a></li><li><a class="nounderline abstract_t">Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007; :CD006356.</a></li><li><a class="nounderline abstract_t">Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009; 68:1833.</a></li><li><a class="nounderline abstract_t">Gøtzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316:811.</a></li><li><a class="nounderline abstract_t">van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914.</a></li><li><a class="nounderline abstract_t">So H, Lam TO, Meng H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis 2023; 82:1387.</a></li><li><a class="nounderline abstract_t">Choy EH, Kingsley GH, Corkill MM, Panayi GS. Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy. Br J Rheumatol 1993; 32:734.</a></li><li><a class="nounderline abstract_t">Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis 2005; 64:1288.</a></li><li><a class="nounderline abstract_t">Verstappen SM, McCoy MJ, Roberts C, et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis 2010; 69:503.</a></li><li><a class="nounderline abstract_t">Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:713.</a></li><li><a class="nounderline abstract_t">Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.</a></li><li><a class="nounderline abstract_t">England BR, Barber CEH, Bergman M, et al. Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. Arthritis Care Res (Hoboken) 2021; 73:1809.</a></li><li><a class="nounderline abstract_t">O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010; 69:1823.</a></li><li><a class="nounderline abstract_t">Lillegraven S, Paulshus Sundlisæter N, Aga AB, et al. Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial. Ann Rheum Dis 2023; 82:1394.</a></li><li><a class="nounderline abstract_t">ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347:347.</a></li><li><a class="nounderline abstract_t">Tiippana-Kinnunen T, Paimela L, Kautiainen H, et al. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol 2010; 39:12.</a></li><li><a class="nounderline abstract_t">Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol 2010; 6:68.</a></li><li><a class="nounderline abstract_t">Berthelot JM, Varin S. Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents? Joint Bone Spine 2004; 71:257.</a></li><li><a class="nounderline abstract_t">Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:319.</a></li><li><a class="nounderline abstract_t">Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 Suppl 1:S3.</a></li></ol></div><div id="topicVersionRevision">Topic 7491 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643696" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20237123" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16258899" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371885" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18438829" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334255" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14730599" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19404945" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15262104" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519278" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567728" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170917" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18512708" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20444750" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545940" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161836" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34101376" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36357155" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17139662" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11690569" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113999" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113999" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796399" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Methotrexate for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10986302" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657072" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025440" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16030080" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884297" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096165" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385520" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9251634" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18438851" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11840435" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Guidelines for the management of rheumatoid arthritis: 2002 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9858426" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19798027" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of rheumatoid arthritis: state of the art 2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31112011" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : TEAR: Treatment of early aggressive RA: A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635256" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16463431" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955534" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23044791" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573044" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888712" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9929017" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508468" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883172" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy of low-dose methotrexate in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037555" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1734901" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7945475" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3893441" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9153566" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24916606" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Methotrexate for treating rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9972956" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Radiologic progression in early rheumatoid arthritis treated with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9972955" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9330927" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term treatment of destructive rheumatoid arthritis with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24941177" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tofacitinib versus methotrexate in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27723271" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32638504" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35081280" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33268527" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665630" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rheumatoid arthritis: strategy more important than agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19917618" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20187135" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15529377" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23686414" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Two-year radiographic results from the TEAR trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20959326" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : State-of-the-art: rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32956604" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9012755" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7791815" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253590" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effects of glucocorticoids on radiological progression in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19066177" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9549450" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18662933" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37487608" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8348277" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during the induction phase of chrysotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15760929" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19825849" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639167" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8639168" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813284" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19224904" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37607809" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598699" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20132065" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20125170" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288847" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22388646" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21624182" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Understanding emerging treatment paradigms in rheumatoid arthritis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
